Please assess the completion status of the following clinical trial:

Trial Title: Cetuximab Plus Radiotherapy Versus Cisplatin Plus Radiotherapy in Locally Advanced Head and Neck Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed squamous cell carcinoma (with biopsy on the primary and / or lymph node metastases) of the oral cavity, oropharynx, hypopharynx, larynx supraglottix;~* Locally advanced disease, defined by one of the following criteria: any T, N +, M0 (excluding T1, N1), T3-4, N0, M0;~* Not cancer nasopharynx or paranasal sinuses or salivary glands;~* General conditions and associated diseases which does not allow to perform chemotherapy or radiotherapy in a radical view;~* No other surgical treatments, chemotherapy or radiotherapy for cancer of head and neck or elsewhere, except non-melanoma skin cancer or in situ cervical cancer and other solid tumors for which radical treatment has been completed \> three years prior to enrollment in the study and for which the patient has remained continuously free of disease;~* Accessibility to follow-up;~* Signing of informed consent;~* Interval between examinations of local staging and randomization, maximum 3 weeks~* Interval between randomization and initiation of treatment, maximum 2 weeks~Exclusion Criteria:~* Age \<18 years~* ECOG performance status \> 0-1~* Hemoglobin \<9 g / dL~* Counts of granulocytes, total \<1.5 x 10 \^ 9 / L~* Platelet count \<100 x 10 \^ 9 / L~* Bilirubin\> 1.5 times upper limit of normal (ULN)~* AST or ALT\> 3 times ULN~* Creatinine clearance \> 50 mL/min~* Mg \> 0.5 mmol/L~* Pregnancy or lactation~* Presence of allergy to study drug or to the excipients used in their formulation~* Peripheral neuropathy ≥ grade 2 (CTCAE v3.0)~* Hearing loss / tinnitus ≥ grade 3 (CTCAE v3.0)~* One of the following conditions:~  * Myocardial infarction within 12 months prior to randomization~ * Severe congestive heart failure~ * Unstable angina~ * Cardiomyopathy in act~ * Ventricular arrhythmia~ * uncontrolled hypertension~ * Severe psychotic disorders in act~ * Severe infection in act~ * Any other serious illness that could interfere with the administration of the therapy provided by the protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- cetuximab plus radiotherapy (Type: EXPERIMENTAL): Cetuximab given one week before radiotherapy (loading dose, 400 mg/m2) plus weekly (250 mg/m2), concomitant with radiotherapy (7O Gy on clinically involved sites).
- cisplatin plus radiotherapy (Type: ACTIVE_COMPARATOR): CDDP 40 mg/mq in a single weekly 1-hour infusion concomitant to radiotherapy: (70 Gy to clinically involved sites)

Based on this trial design, predict the completion outcome and termination type (if applicable).